Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1/2 study of Betalutin in relapsed non-Hodgkin B-cell lymphoma
MOH_2018-11-19_004765Phase 2Recruiting
- Sponsor
- Nordic Nanovector ASA
- Start
- Jul 2018
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta-minus Emitters → Radiopharmaceuticals
- Countries
- 1
01
Overview
Phase 2, open-label trial of lutetium (177Lu) lilotomab satetraxetan in non-Hodgkin lymphoma (NHL) and mature B-cell lymphoma (2 arms), sponsored by Nordic Nanovector ASA. Primary endpoints: Efficacy and Safety. Started Jul 2018; status: recruiting.
02
Drugs
lutetium (177Lu) lilotomab satetraxetan
03
Conditions
non-Hodgkin lymphoma (NHL)mature B-cell lymphoma
Beyond the preview
Go deeper on MOH_2018-11-19_004765.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2018-11-19_004765.